RT Journal Article
SR Electronic
T1 Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.08.21254791
DO 10.1101/2021.04.08.21254791
A1 Chen, Liang
A1 Zody, Michael C
A1 Mediavilla, Jose R
A1 Cunningham, Marcus H
A1 Composto, Kaelea
A1 Chow, Kar Fai
A1 Kordalewska, Milena
A1 Corvelo, André
A1 Oschwald, Dayna M
A1 Fennessey, Samantha
A1 Zetkulic, Marygrace
A1 Dar, Sophia
A1 Kramer, Yael
A1 Mathema, Barun
A1 Maniatis, Tom
A1 Perlin, David S
A1 Kreiswirth, Barry N
YR 2021
UL http://medrxiv.org/content/early/2021/04/11/2021.04.08.21254791.abstract
AB SARS-CoV-2 Variants of Concerns (VOC), e.g., B.1.351 (20H/501Y.V2) and P1 (20J/501Y.V3), harboring N-terminal domain (NTD) or the receptor-binding domain (RBD) (e.g., E484K) mutations, exhibit reduced in vitro susceptibility to convalescent serum, commercial antibody cocktails, and vaccine neutralization, and have been associated with reinfection. The accumulation of these mutations could be the consequence of intra-host viral evolution due to prolonged infection in immunocompromised hosts. In this study, we document the microevolution of SARS-CoV-2 recovered from sequential tracheal aspirates from an immunosuppressed patient on tacrolimus, steroids and convalescent plasma therapy, and identify the emergence of multiple NTD and RBD mutations associated with reduced antibody neutralization as early as three weeks after infection. SARS-CoV-2 genomes from the first swab (Day 0) and three tracheal aspirates (Day 7, 21 and 27) were compared at the sequence level. We identified five different S protein mutations at the NTD or RBD regions from the second tracheal aspirate sample (21 Day). The S:Q493R substitution and S:243-244LA deletion had ∼70% frequency, while ORF1a:A138T, S:141-144LGVY deletion, S:E484K and S:Q493K substitutions demonstrated ∼30%, ∼30%, ∼20% and ∼10% mutation frequency, respectively. However, the third tracheal aspirate sample collected one week later (Day 27) was predominated by the haplotype of ORF1a:A138T, S:141-144LGVY deletion and S:E484K (> 95% mutation frequency). Notably, S protein deletions (141-144LGVY and 243-244LA deletions in NTD region) and substitutions (Q493K/R and E484K in the RBD region) previously showed reduced susceptibly to monoclonal antibody or convalescent plasma. The observation supports the hypothesis that VOCs can independently arise and that immunocompromised patients on convalescent plasma therapy are potential breeding grounds for immune-escape mutants.Competing Interest Statement The authors have declared no competing interest.Funding Statement The study was in part supported by Center for Discovery and Innovation and Hackensack Meridian Health Foundation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was in part supported by Center for Discovery and Innovation and Hackensack Meridian Health Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from this patient and the study was approved by Hackensack Meridian Health Institutional Review Board (IRB) under protocol Pro2018-1022.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data were deposited in the National. Center for Biotechnology Information database under. BioProject PRJNA675117.